The Times: The headline rate of inflation fell more than expected in November to a 10-month low – increasing expectations that the Bank of England will cut interest rates tomorrow. The
The Times: The headline rate of inflation fell more than expected in November to a 10-month low – increasing expectations that the Bank of England will cut interest rates tomorrow. The
The broader market was quiet for small-cap stocks this week. The AIM All-Share index rose slightly, gaining fewer than two points to close at 775.68. This was a marginal outperformance
Collaboration combines N4 Pharma’s innovative Nuvec® delivery platform with CMAC’s world-class expertise to accelerate development and broaden therapeutic applications
N4 Pharma PLC (AIM: N4P) shares surged after the company announced that its Nuvec® delivery system had successfully targeted non-small cell lung cancer cells in collaboration with leading US research
Fiinu (BANK), a fintech group and creator of the Plugin Overdraft®, announces that it has entered into an unsecured Sterling term loan facility agreement with Conister Bank Limited, the wholly owned
Alliance News: Migrants will be told they need to spend up to a decade in the UK before they can apply for citizenship and English language requirements will be increased as
N4 Pharma plc (AIM: N4P), the biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to announce the appointment of Dr
N4 Pharma CEO Q&A Now LIVE
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s charts are FTSE 100, Dax, Dow, Bitcoin, Gold, Atome, Adriatic,
The tug of war continues between the reports in the financial media, and indeed, a Goldman Sachs warning about the London stock market, and the FTSE 100 going to new
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system designed to carry nucleotides to be developed as cancer treatments and vaccines, is delighted to
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide a further positive update on its